Details of the Drug Pharmacogenomic Perturbation Atlas

PF-03772304 Drug Info

MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth

Cross-matching ID

TTD Drug ID

D05RSS

General Information of Drug (ID: DMJ0936)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Notch signaling pathway	1.88	3.64e-2	49/59 (83.05%)	TLE1;RFNG;DVL1;...
DNA replication	-1.67	4.30e-2	34/36 (94.44%)	DNA2;MCM6;POLD2;...
Glycolysis / Gluconeogenesis	-1.68	4.37e-2	56/67 (83.58%)	GCK;HK2;PDHA1;...
Ribosome biogenesis in eukaryotes	-1.69	3.70e-2	52/108 (48.15%)	RAN;RBM28;NHP2;...
Rheumatoid arthritis	-1.70	3.92e-2	78/93 (83.87%)	ANGPT1;HLA-DOB;FOS;...
Arginine and proline metabolism	-1.70	4.27e-2	39/50 (78%)	CKB;ALDH18A1;SRM;...
Glycine, serine and threonine metabolism	-1.76	2.62e-2	31/40 (77.5%)	GCAT;SHMT2;DLD;...
Glutathione metabolism	-1.79	1.94e-2	43/57 (75.44%)	GPX7;RRM2;GSTM3;...
Prion disease	-1.82	1.64e-2	209/273 (76.56%)	KIF5A;SDHC;GRIN2A;...
Biosynthesis of unsaturated fatty acids	-1.83	1.72e-2	21/27 (77.78%)	HACD2;TECR;SCP2;...
IL-17 signaling pathway	-1.90	7.29e-3	84/94 (89.36%)	NFKB1;IL17A;CSF2;...
Legionellosis	-1.90	8.74e-3	51/57 (89.47%)	CXCL3;NFKB1;RAB1B;...
Terpenoid backbone biosynthesis	-1.90	1.09e-2	18/22 (81.82%)	DHDDS;HMGCR;ICMT;...
Proteasome	-2.25	0.00e+0	44/46 (95.65%)	PSMD8;PSMD3;PSMC6;...
Protein processing in endoplasmic reticulum	-2.26	0.00e+0	127/171 (74.27%)	DNAJA2;MAPK10;PDIA4;...
Steroid biosynthesis	-2.30	0.00e+0	19/20 (95%)	LSS;HSD17B7;SC5D;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast carcinoma

Normal (Epithelial)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HME1	CVCL_2950	Homo sapiens	0.0001uM - 10uM	3H, 24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Transformed)

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Fibroblast)

Peripheral blood

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H